Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05225389 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
A Phase 1 study, sponsored by Cognition Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05225389: Completed Phase 1 study, sponsored by Cognition Therapeutics.
NCT05225389 is a Phase 1 study that has completed, run by Cognition Therapeutics. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05225389, a Phase 1 study, has completed, sponsored by Cognition Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812
Primary Outcome
Plasma concentrations of CT1812 were determined using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) following a single oral dose of 300 mg (\~1 μCi) \[14C\]-CT1812 administered in healthy adult male subjects.
Interventions
- DRUG 300 mg [C14] CT1812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-12-31 |
| Est. Completion | 2022-01-24 |
| Phase | Phase 1 |
What the finished NCT05225389 record still lists
NCT05225389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which 300 mg [C14] CT1812 is the first listed.
NCT05225389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05225389 about?
NCT05225389 is a clinical study titled "Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects". Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812
What is the current status of trial NCT05225389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-12-31. Estimated completion is 2022-01-24.
What interventions are being tested in trial NCT05225389?
The interventions under investigation include: 300 mg [C14] CT1812 (DRUG).
Who is sponsoring clinical trial NCT05225389?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05225389's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI